EyePoint Pharmaceuticals (EYPT) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

EYPT EyePoint Pharmaceuticals

Watchlist

9.110
-0.110-1.19%

Close Jan 8 16:00 ET

9.110
0.0000.00%

Post 20:01 ET

621.77MMarket Cap-4.58P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Optimistic Buy Rating for EyePoint Pharmaceuticals: Potential of Duravyu in Diabetic Macular Edema
TipRanks11:26 ET · Ratings
EyePoint Pharmaceuticals Strengthens Board With New Appointment
TipRanksJan 8 07:30 ET
Express News | EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.d., Fasrs to Board of Directors
ReutersJan 8 07:00 ET
EyePoint Appoints Reginald Sanders to Board of Directors
Dow JonesJan 8 07:00 ET
EyePoint Initiated at Buy by Citi on WAMD Drug Potential
Seeking AlphaJan 7 13:37 ET
Citi Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $33
Moomoo NewsJan 7 06:31 ET · Ratings

Comments

Jaguar8

Nov 7, 2024 21:34

13G

$EyePoint Pharmaceuticals (EYPT.US)$
EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(5.2%),TCG Crossover Fund II, L.P.(5.2%), etc.

Jaguar8

Nov 7, 2024 15:14

NEWS ER

$EyePoint Pharmaceuticals (EYPT.US)$
Positive
Positive interim DME trial data showing significant BCVA improvement of +8.9 letters
Successful completion of $161M equity financing
Extended cash runway into 2027
Initiation of Phase 3 LUGANO trial in wet AMD
Opening of new 40,000 sq ft cGMP manufacturing facility
Negative
Revenue declined 31% YoY to $10.5M from $15.2M
Net loss increased to $29.4M from $12.6M YoY
Operating expenses increased to $43.3M from $29.6M YoY
Cash position decreased to...

Trytosaveabit

Oct 28, 2024 16:25

Oophff news

$EyePoint Pharmaceuticals (EYPT.US)$ Reuters· 8 mins ago
EyePoint Pharmaceuticals Inc - Commences $100 Million Public Offering

Stock_Drift

Oct 28, 2024 10:08

Unusual Volume Ticks. 11:07am 10/28

$Fractyl Health (GUTS.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$ $Oklo Inc (OKLO.US)$ $Revance Therapeutics (RVNC.US)$ $PROCEPT BioRobotics (PRCT.US)$ $Atlas Lithium (ATLX.US)$ $EyePoint Pharmaceuticals (EYPT.US)$ $Porch Group (PRCH.US)$ $Top Wealth Group Holding (TWG.US)$ $Global Mofy AI (GMM.US)$ $Monte Rosa Therapeutics (GLUE.US)$ $Evoke Pharma (EVOK.US)$ $Greenlane (GNLN.US)$ $Autonomix Medical (AMIX.US)$ $Healthcare Triangle (HCTI.US)$
📊⚡️📊

Trytosaveabit

Oct 28, 2024 06:07

Update

$EyePoint Pharmaceuticals (EYPT.US)$ EyePoint's DURAVYU Shows Results for Diabetic Macular Edema, Improving Vision and Anatomy in Early Trial Data! Favorable Safety Profile Continues With No Duravyu-Related Ocular or Systemic Saes to Date
Benzinga· 2 mins ago

Heat List

Overall

No Data